Literature DB >> 16081794

IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response.

Yongqing Li1, Marie Bleakley, Cassian Yee.   

Abstract

IL-21, a newly described cytokine belonging to the IL-2 gamma-chain receptor cytokine family (that includes IL-2, IL-7, and IL-15), has been described as an important regulator of the cellular immune response. In this study, the role of IL-21 in the generation of a human Ag-specific CD8+ T cell response is characterized by tracking a rare, but measurable population of self-Ag-specific T cells in vitro. Autologous dendritic cells pulsed with the melanoma antigen recognized T cells 1 self-peptide were used to stimulate CD8+ T cells from HLA-A2+ healthy donors and melanoma patients. We demonstrate that exposure to IL-21 increased the total number of MART-1-specific CD8+ T cells that could be elicited by >20-fold and, at the clonal level, enriched for a population of high-affinity CD8+ T cells with a peptide dose requirement more than 1 log(10)-fold less than their untreated counterparts. Phenotypic analysis of T cells from IL-21-treated cultures revealed a unique population of CD45RO+ CD28(high) CD8+ T cells, a phenotype that was stable for at least 4 wk after IL-21 exposure. These CD28(high) CD8+ T cells produced IL-2 upon Ag stimulation and represent potential helper-independent CTLs. Our studies demonstrate a significant role for IL-21 in the primary Ag-specific human CTL response and support the use of IL-21 in the ex vivo generation of potent Ag-specific CTLs for adoptive therapy or as an adjuvant cytokine during in vivo immunization against tumor Ags.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081794     DOI: 10.4049/jimmunol.175.4.2261

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  117 in total

1.  NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.

Authors:  Nobuyoshi Hanaoka; Bana Jabri; Zhenpeng Dai; Cezary Ciszewski; Anne M Stevens; Cassian Yee; Hideki Nakakuma; Thomas Spies; Veronika Groh
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

Review 2.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

Review 3.  Multiple vaccinations: friend or foe.

Authors:  Sarah E Church; Shawn M Jensen; Christopher G Twitty; Keith Bahjat; Hong-Ming Hu; Walter J Urba; Bernard A Fox
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 4.  Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.

Authors:  Lauren McLaughlin; C Russell Cruz; Catherine M Bollard
Journal:  Ther Adv Hematol       Date:  2015-12

5.  SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.

Authors:  Jungsun Park; Amjad H Talukder; Seon A Lim; Kwanghee Kim; Ke Pan; Brenda Melendez; Sherille D Bradley; Kyle R Jackson; Jahan S Khalili; Junmei Wang; Caitlin Creasy; Bih-Fang Pan; Scott E Woodman; Chantale Bernatchez; David Hawke; Patrick Hwu; Kyung-Mi Lee; Jason Roszik; Gregory Lizée; Cassian Yee
Journal:  Cancer Immunol Res       Date:  2017-06-19       Impact factor: 11.151

Review 6.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.

Authors:  Joseph G Crompton; Madhusudhanan Sukumar; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

9.  Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I.

Authors:  Aude G Chapuis; Olga K Afanasiev; Jayasri G Iyer; Kelly G Paulson; Upendra Parvathaneni; Joo Ha Hwang; Ivy Lai; Ilana M Roberts; Heather L Sloan; Shailender Bhatia; Kendall C Shibuya; Ted Gooley; Cindy Desmarais; David M Koelle; Cassian Yee; Paul Nghiem
Journal:  Cancer Immunol Res       Date:  2014-01       Impact factor: 11.151

Review 10.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.